ELIFE HLDGS: Forensic investigation and internal control review have been completed, trading suspension continues

ELIFE HLDGS (00223.HK) announced that the forensic investigation and internal control review regarding the company's delay in issuing the 2024 interim results and report have been completed. The independent investigator appointed by the company, KPMG, has completed the forensic investigation, which included allegations of unusual transactions involving former board members related to the company's Chinese subsidiaries, as well as issues related to missing documents concerning revenue, costs, and investment activities. The report has been submitted to the Hong Kong Stock Exchange for review.

At the same time, the internal control review and follow-up review commissioned by the company, conducted by Deloitte, have been completed, covering the group's internal control systems and procedures from April 2024 to March 2025. The report has also been submitted to the Hong Kong Stock Exchange.

At the request of ELIFE HLDGS, trading of its shares has been suspended since December 2, 2024, and will remain suspended until further notice

Source: AASTOCKS The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.